Literature DB >> 34340233

CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients.

Zerrin Karaaslan1, Murat Kurtuncu2, Halil İbrahim Akcay2, Tuncay Gunduz2, Burcu Altunrende3, Recai Turkoglu4, Mefkure Eraksoy2, Canan Ulusoy5, Vuslat Yilmaz5, Erdem Tüzün5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34340233     DOI： 10.1159/000517770

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


× No keyword cloud information.
  1 in total

Review 1.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.